nodes	percent_of_prediction	percent_of_DWPC	metapath
Naratriptan—migraine—Prednisone—Crohn's disease	0.902	1	CpDpCtD
Naratriptan—Gastrointestinal discomfort—Azathioprine—Crohn's disease	0.00383	0.047	CcSEcCtD
Naratriptan—Pleurisy—Mesalazine—Crohn's disease	0.00324	0.0398	CcSEcCtD
Naratriptan—Ulcer—Mercaptopurine—Crohn's disease	0.00154	0.0189	CcSEcCtD
Naratriptan—Micturition urgency—Mesalazine—Crohn's disease	0.0014	0.0171	CcSEcCtD
Naratriptan—Haemorrhoids—Mesalazine—Crohn's disease	0.00135	0.0165	CcSEcCtD
Naratriptan—Burning sensation—Mesalazine—Crohn's disease	0.00114	0.014	CcSEcCtD
Naratriptan—Dermatitis atopic—Mesalazine—Crohn's disease	0.00107	0.0131	CcSEcCtD
Naratriptan—Scotoma—Mesalazine—Crohn's disease	0.00104	0.0128	CcSEcCtD
Naratriptan—Hyperaesthesia—Mesalazine—Crohn's disease	0.00101	0.0124	CcSEcCtD
Naratriptan—Feeling hot—Mesalazine—Crohn's disease	0.00101	0.0124	CcSEcCtD
Naratriptan—Cognitive disorder—Prednisone—Crohn's disease	0.000969	0.0119	CcSEcCtD
Naratriptan—Blood disorder—Mesalazine—Crohn's disease	0.000948	0.0116	CcSEcCtD
Naratriptan—Musculoskeletal stiffness—Mesalazine—Crohn's disease	0.000883	0.0108	CcSEcCtD
Naratriptan—Vaginal inflammation—Mesalazine—Crohn's disease	0.000792	0.00973	CcSEcCtD
Naratriptan—Cystitis noninfective—Mesalazine—Crohn's disease	0.000773	0.0095	CcSEcCtD
Naratriptan—Cystitis—Mesalazine—Crohn's disease	0.000765	0.00939	CcSEcCtD
Naratriptan—Vaginal infection—Mesalazine—Crohn's disease	0.000748	0.00918	CcSEcCtD
Naratriptan—Dry eye—Mesalazine—Crohn's disease	0.000731	0.00898	CcSEcCtD
Naratriptan—Bladder pain—Mesalazine—Crohn's disease	0.000716	0.00879	CcSEcCtD
Naratriptan—Immune system disorder—Mercaptopurine—Crohn's disease	0.000662	0.00813	CcSEcCtD
Naratriptan—Photosensitivity—Mesalazine—Crohn's disease	0.000655	0.00804	CcSEcCtD
Naratriptan—Hypothyroidism—Prednisone—Crohn's disease	0.000653	0.00802	CcSEcCtD
Naratriptan—Gastroenteritis—Mesalazine—Crohn's disease	0.000648	0.00797	CcSEcCtD
Naratriptan—Alopecia—Mercaptopurine—Crohn's disease	0.000647	0.00795	CcSEcCtD
Naratriptan—Eye pain—Mesalazine—Crohn's disease	0.000637	0.00782	CcSEcCtD
Naratriptan—Libido decreased—Mesalazine—Crohn's disease	0.00062	0.00761	CcSEcCtD
Naratriptan—Atrial fibrillation—Mesalazine—Crohn's disease	0.000607	0.00745	CcSEcCtD
Naratriptan—Thirst—Mesalazine—Crohn's disease	0.000604	0.00742	CcSEcCtD
Naratriptan—Anaemia—Mercaptopurine—Crohn's disease	0.000589	0.00724	CcSEcCtD
Naratriptan—Disturbance in sexual arousal—Mesalazine—Crohn's disease	0.00057	0.007	CcSEcCtD
Naratriptan—Dermatitis atopic—Prednisone—Crohn's disease	0.000566	0.00695	CcSEcCtD
Naratriptan—Migraine—Mesalazine—Crohn's disease	0.000566	0.00695	CcSEcCtD
Naratriptan—Neuritis—Prednisone—Crohn's disease	0.000561	0.00689	CcSEcCtD
Naratriptan—Arthralgia—Mercaptopurine—Crohn's disease	0.000543	0.00667	CcSEcCtD
Naratriptan—Liver function test abnormal—Mesalazine—Crohn's disease	0.000531	0.00652	CcSEcCtD
Naratriptan—Dry skin—Mesalazine—Crohn's disease	0.000527	0.00647	CcSEcCtD
Naratriptan—Abdominal discomfort—Azathioprine—Crohn's disease	0.000523	0.00642	CcSEcCtD
Naratriptan—Oedema—Mercaptopurine—Crohn's disease	0.00052	0.00639	CcSEcCtD
Naratriptan—Cramp muscle—Mesalazine—Crohn's disease	0.000518	0.00636	CcSEcCtD
Naratriptan—Glycosuria—Prednisone—Crohn's disease	0.000517	0.00635	CcSEcCtD
Naratriptan—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.00051	0.00626	CcSEcCtD
Naratriptan—Gastritis—Mesalazine—Crohn's disease	0.000509	0.00625	CcSEcCtD
Naratriptan—Skin disorder—Mercaptopurine—Crohn's disease	0.000506	0.00621	CcSEcCtD
Naratriptan—Asthma—Mesalazine—Crohn's disease	0.000497	0.0061	CcSEcCtD
Naratriptan—Pneumonia—Azathioprine—Crohn's disease	0.000489	0.00601	CcSEcCtD
Naratriptan—Angina pectoris—Mesalazine—Crohn's disease	0.000484	0.00594	CcSEcCtD
Naratriptan—Bronchitis—Mesalazine—Crohn's disease	0.000478	0.00587	CcSEcCtD
Naratriptan—Abdominal discomfort—Mesalazine—Crohn's disease	0.000476	0.00585	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.000474	0.00583	CcSEcCtD
Naratriptan—Pollakiuria—Mesalazine—Crohn's disease	0.000459	0.00564	CcSEcCtD
Naratriptan—Photosensitivity reaction—Mesalazine—Crohn's disease	0.000453	0.00557	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.000449	0.00552	CcSEcCtD
Naratriptan—Pneumonia—Mesalazine—Crohn's disease	0.000446	0.00547	CcSEcCtD
Naratriptan—Hypercholesterolaemia—Prednisone—Crohn's disease	0.000443	0.00544	CcSEcCtD
Naratriptan—Ulcer—Prednisone—Crohn's disease	0.000443	0.00544	CcSEcCtD
Naratriptan—Depression—Mesalazine—Crohn's disease	0.000442	0.00543	CcSEcCtD
Naratriptan—Haemoglobin—Azathioprine—Crohn's disease	0.000439	0.00539	CcSEcCtD
Naratriptan—Haemorrhage—Azathioprine—Crohn's disease	0.000437	0.00536	CcSEcCtD
Naratriptan—Neuropathy peripheral—Mesalazine—Crohn's disease	0.000434	0.00533	CcSEcCtD
Naratriptan—Sweating—Mesalazine—Crohn's disease	0.000425	0.00522	CcSEcCtD
Naratriptan—Sinusitis—Mesalazine—Crohn's disease	0.000416	0.0051	CcSEcCtD
Naratriptan—Body temperature increased—Mercaptopurine—Crohn's disease	0.000411	0.00505	CcSEcCtD
Naratriptan—Haemoglobin—Mesalazine—Crohn's disease	0.0004	0.00491	CcSEcCtD
Naratriptan—Fluid retention—Prednisone—Crohn's disease	0.000398	0.00489	CcSEcCtD
Naratriptan—Haemorrhage—Mesalazine—Crohn's disease	0.000398	0.00488	CcSEcCtD
Naratriptan—Immune system disorder—Azathioprine—Crohn's disease	0.000394	0.00484	CcSEcCtD
Naratriptan—Chills—Azathioprine—Crohn's disease	0.000392	0.00481	CcSEcCtD
Naratriptan—Arrhythmia—Azathioprine—Crohn's disease	0.00039	0.00479	CcSEcCtD
Naratriptan—Alopecia—Azathioprine—Crohn's disease	0.000386	0.00474	CcSEcCtD
Naratriptan—Hypersensitivity—Mercaptopurine—Crohn's disease	0.000383	0.00471	CcSEcCtD
Naratriptan—Oesophagitis—Prednisone—Crohn's disease	0.000383	0.0047	CcSEcCtD
Naratriptan—Tinnitus—Mesalazine—Crohn's disease	0.000371	0.00455	CcSEcCtD
Naratriptan—Cardiac disorder—Mesalazine—Crohn's disease	0.000369	0.00453	CcSEcCtD
Naratriptan—Hyperkinesia—Prednisone—Crohn's disease	0.000365	0.00449	CcSEcCtD
Naratriptan—Angiopathy—Mesalazine—Crohn's disease	0.000361	0.00443	CcSEcCtD
Naratriptan—Immune system disorder—Mesalazine—Crohn's disease	0.000359	0.00441	CcSEcCtD
Naratriptan—Chills—Mesalazine—Crohn's disease	0.000357	0.00438	CcSEcCtD
Naratriptan—Diarrhoea—Mercaptopurine—Crohn's disease	0.000356	0.00437	CcSEcCtD
Naratriptan—Ill-defined disorder—Azathioprine—Crohn's disease	0.000353	0.00433	CcSEcCtD
Naratriptan—Alopecia—Mesalazine—Crohn's disease	0.000351	0.00432	CcSEcCtD
Naratriptan—Anaemia—Azathioprine—Crohn's disease	0.000351	0.00431	CcSEcCtD
Naratriptan—Erythema—Mesalazine—Crohn's disease	0.000346	0.00425	CcSEcCtD
Naratriptan—Malaise—Azathioprine—Crohn's disease	0.000343	0.00421	CcSEcCtD
Naratriptan—Vascular purpura—Prednisone—Crohn's disease	0.00034	0.00418	CcSEcCtD
Naratriptan—Muscle spasms—Mesalazine—Crohn's disease	0.000333	0.00409	CcSEcCtD
Naratriptan—Vomiting—Mercaptopurine—Crohn's disease	0.000331	0.00407	CcSEcCtD
Naratriptan—Rash—Mercaptopurine—Crohn's disease	0.000328	0.00403	CcSEcCtD
Naratriptan—Dermatitis—Mercaptopurine—Crohn's disease	0.000328	0.00403	CcSEcCtD
Naratriptan—Vision blurred—Mesalazine—Crohn's disease	0.000326	0.00401	CcSEcCtD
Naratriptan—Tremor—Mesalazine—Crohn's disease	0.000324	0.00398	CcSEcCtD
Naratriptan—Arthralgia—Azathioprine—Crohn's disease	0.000324	0.00397	CcSEcCtD
Naratriptan—Myalgia—Azathioprine—Crohn's disease	0.000324	0.00397	CcSEcCtD
Naratriptan—Ill-defined disorder—Mesalazine—Crohn's disease	0.000321	0.00395	CcSEcCtD
Naratriptan—Anaemia—Mesalazine—Crohn's disease	0.00032	0.00393	CcSEcCtD
Naratriptan—Discomfort—Azathioprine—Crohn's disease	0.00032	0.00393	CcSEcCtD
Naratriptan—Purpura—Prednisone—Crohn's disease	0.000316	0.00388	CcSEcCtD
Naratriptan—Malaise—Mesalazine—Crohn's disease	0.000312	0.00383	CcSEcCtD
Naratriptan—Vertigo—Mesalazine—Crohn's disease	0.000311	0.00382	CcSEcCtD
Naratriptan—Syncope—Mesalazine—Crohn's disease	0.00031	0.00381	CcSEcCtD
Naratriptan—Nausea—Mercaptopurine—Crohn's disease	0.000309	0.0038	CcSEcCtD
Naratriptan—Infection—Azathioprine—Crohn's disease	0.000308	0.00378	CcSEcCtD
Naratriptan—Palpitations—Mesalazine—Crohn's disease	0.000306	0.00376	CcSEcCtD
Naratriptan—Loss of consciousness—Mesalazine—Crohn's disease	0.000304	0.00374	CcSEcCtD
Naratriptan—Thrombocytopenia—Azathioprine—Crohn's disease	0.000304	0.00373	CcSEcCtD
Naratriptan—Cough—Mesalazine—Crohn's disease	0.000302	0.00371	CcSEcCtD
Naratriptan—Skin disorder—Azathioprine—Crohn's disease	0.000301	0.0037	CcSEcCtD
Naratriptan—Arthralgia—Mesalazine—Crohn's disease	0.000295	0.00362	CcSEcCtD
Naratriptan—Myalgia—Mesalazine—Crohn's disease	0.000295	0.00362	CcSEcCtD
Naratriptan—Anxiety—Mesalazine—Crohn's disease	0.000294	0.00361	CcSEcCtD
Naratriptan—Discomfort—Mesalazine—Crohn's disease	0.000291	0.00358	CcSEcCtD
Naratriptan—Hypotension—Azathioprine—Crohn's disease	0.00029	0.00356	CcSEcCtD
Naratriptan—Dry mouth—Mesalazine—Crohn's disease	0.000288	0.00354	CcSEcCtD
Naratriptan—Confusional state—Mesalazine—Crohn's disease	0.000285	0.0035	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.000283	0.00347	CcSEcCtD
Naratriptan—Anaphylactic shock—Mesalazine—Crohn's disease	0.000282	0.00347	CcSEcCtD
Naratriptan—Oedema—Mesalazine—Crohn's disease	0.000282	0.00347	CcSEcCtD
Naratriptan—Infection—Mesalazine—Crohn's disease	0.000281	0.00345	CcSEcCtD
Naratriptan—Dry skin—Prednisone—Crohn's disease	0.000279	0.00342	CcSEcCtD
Naratriptan—Shock—Mesalazine—Crohn's disease	0.000278	0.00341	CcSEcCtD
Naratriptan—Nervous system disorder—Mesalazine—Crohn's disease	0.000277	0.0034	CcSEcCtD
Naratriptan—Thrombocytopenia—Mesalazine—Crohn's disease	0.000277	0.0034	CcSEcCtD
Naratriptan—Skin disorder—Mesalazine—Crohn's disease	0.000274	0.00337	CcSEcCtD
Naratriptan—Hyperhidrosis—Mesalazine—Crohn's disease	0.000273	0.00335	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.000268	0.00329	CcSEcCtD
Naratriptan—Hypotension—Mesalazine—Crohn's disease	0.000264	0.00324	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.000257	0.00316	CcSEcCtD
Naratriptan—Feeling abnormal—Azathioprine—Crohn's disease	0.000256	0.00314	CcSEcCtD
Naratriptan—Paraesthesia—Mesalazine—Crohn's disease	0.000254	0.00312	CcSEcCtD
Naratriptan—Dyspnoea—Mesalazine—Crohn's disease	0.000252	0.00309	CcSEcCtD
Naratriptan—Somnolence—Mesalazine—Crohn's disease	0.000251	0.00309	CcSEcCtD
Naratriptan—Body temperature increased—Azathioprine—Crohn's disease	0.000245	0.00301	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.000244	0.003	CcSEcCtD
Naratriptan—Fatigue—Mesalazine—Crohn's disease	0.000244	0.00299	CcSEcCtD
Naratriptan—Pain—Mesalazine—Crohn's disease	0.000242	0.00297	CcSEcCtD
Naratriptan—Constipation—Mesalazine—Crohn's disease	0.000242	0.00297	CcSEcCtD
Naratriptan—Hyperglycaemia—Prednisone—Crohn's disease	0.000237	0.00291	CcSEcCtD
Naratriptan—Depression—Prednisone—Crohn's disease	0.000234	0.00287	CcSEcCtD
Naratriptan—Feeling abnormal—Mesalazine—Crohn's disease	0.000233	0.00286	CcSEcCtD
Naratriptan—Acute coronary syndrome—Prednisone—Crohn's disease	0.000231	0.00284	CcSEcCtD
Naratriptan—Myocardial infarction—Prednisone—Crohn's disease	0.00023	0.00282	CcSEcCtD
Naratriptan—Neuropathy peripheral—Prednisone—Crohn's disease	0.00023	0.00282	CcSEcCtD
Naratriptan—Hypersensitivity—Azathioprine—Crohn's disease	0.000228	0.00281	CcSEcCtD
Naratriptan—Urticaria—Mesalazine—Crohn's disease	0.000224	0.00276	CcSEcCtD
Naratriptan—Body temperature increased—Mesalazine—Crohn's disease	0.000223	0.00274	CcSEcCtD
Naratriptan—Bradycardia—Prednisone—Crohn's disease	0.000214	0.00263	CcSEcCtD
Naratriptan—Diarrhoea—Azathioprine—Crohn's disease	0.000212	0.00261	CcSEcCtD
Naratriptan—Haemoglobin—Prednisone—Crohn's disease	0.000211	0.0026	CcSEcCtD
Naratriptan—Haemorrhage—Prednisone—Crohn's disease	0.00021	0.00258	CcSEcCtD
Naratriptan—Hallucination—Prednisone—Crohn's disease	0.000209	0.00257	CcSEcCtD
Naratriptan—Hypersensitivity—Mesalazine—Crohn's disease	0.000208	0.00256	CcSEcCtD
Naratriptan—Dizziness—Azathioprine—Crohn's disease	0.000205	0.00252	CcSEcCtD
Naratriptan—Asthenia—Mesalazine—Crohn's disease	0.000203	0.00249	CcSEcCtD
Naratriptan—Pruritus—Mesalazine—Crohn's disease	0.0002	0.00246	CcSEcCtD
Naratriptan—Vomiting—Azathioprine—Crohn's disease	0.000197	0.00242	CcSEcCtD
Naratriptan—Rash—Azathioprine—Crohn's disease	0.000196	0.0024	CcSEcCtD
Naratriptan—Dermatitis—Azathioprine—Crohn's disease	0.000195	0.0024	CcSEcCtD
Naratriptan—Headache—Azathioprine—Crohn's disease	0.000194	0.00239	CcSEcCtD
Naratriptan—Diarrhoea—Mesalazine—Crohn's disease	0.000193	0.00237	CcSEcCtD
Naratriptan—Angiopathy—Prednisone—Crohn's disease	0.000191	0.00234	CcSEcCtD
Naratriptan—Immune system disorder—Prednisone—Crohn's disease	0.00019	0.00233	CcSEcCtD
Naratriptan—Arrhythmia—Prednisone—Crohn's disease	0.000188	0.00231	CcSEcCtD
Naratriptan—Dizziness—Mesalazine—Crohn's disease	0.000187	0.00229	CcSEcCtD
Naratriptan—Alopecia—Prednisone—Crohn's disease	0.000186	0.00228	CcSEcCtD
Naratriptan—Nausea—Azathioprine—Crohn's disease	0.000184	0.00226	CcSEcCtD
Naratriptan—Erythema—Prednisone—Crohn's disease	0.000183	0.00225	CcSEcCtD
Naratriptan—Vomiting—Mesalazine—Crohn's disease	0.00018	0.00221	CcSEcCtD
Naratriptan—Rash—Mesalazine—Crohn's disease	0.000178	0.00219	CcSEcCtD
Naratriptan—Dermatitis—Mesalazine—Crohn's disease	0.000178	0.00219	CcSEcCtD
Naratriptan—Headache—Mesalazine—Crohn's disease	0.000177	0.00217	CcSEcCtD
Naratriptan—Vision blurred—Prednisone—Crohn's disease	0.000173	0.00212	CcSEcCtD
Naratriptan—Ill-defined disorder—Prednisone—Crohn's disease	0.00017	0.00209	CcSEcCtD
Naratriptan—Anaemia—Prednisone—Crohn's disease	0.000169	0.00208	CcSEcCtD
Naratriptan—Agitation—Prednisone—Crohn's disease	0.000168	0.00207	CcSEcCtD
Naratriptan—Nausea—Mesalazine—Crohn's disease	0.000168	0.00206	CcSEcCtD
Naratriptan—Malaise—Prednisone—Crohn's disease	0.000165	0.00203	CcSEcCtD
Naratriptan—Vertigo—Prednisone—Crohn's disease	0.000165	0.00202	CcSEcCtD
Naratriptan—Syncope—Prednisone—Crohn's disease	0.000164	0.00202	CcSEcCtD
Naratriptan—Loss of consciousness—Prednisone—Crohn's disease	0.000161	0.00198	CcSEcCtD
Naratriptan—Convulsion—Prednisone—Crohn's disease	0.000159	0.00195	CcSEcCtD
Naratriptan—Arthralgia—Prednisone—Crohn's disease	0.000156	0.00192	CcSEcCtD
Naratriptan—Myalgia—Prednisone—Crohn's disease	0.000156	0.00192	CcSEcCtD
Naratriptan—Anxiety—Prednisone—Crohn's disease	0.000155	0.00191	CcSEcCtD
Naratriptan—Discomfort—Prednisone—Crohn's disease	0.000154	0.00189	CcSEcCtD
Naratriptan—Anaphylactic shock—Prednisone—Crohn's disease	0.000149	0.00184	CcSEcCtD
Naratriptan—Oedema—Prednisone—Crohn's disease	0.000149	0.00184	CcSEcCtD
Naratriptan—Infection—Prednisone—Crohn's disease	0.000148	0.00182	CcSEcCtD
Naratriptan—Shock—Prednisone—Crohn's disease	0.000147	0.00181	CcSEcCtD
Naratriptan—Nervous system disorder—Prednisone—Crohn's disease	0.000147	0.0018	CcSEcCtD
Naratriptan—Skin disorder—Prednisone—Crohn's disease	0.000145	0.00178	CcSEcCtD
Naratriptan—Hyperhidrosis—Prednisone—Crohn's disease	0.000144	0.00177	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000136	0.00167	CcSEcCtD
Naratriptan—Paraesthesia—Prednisone—Crohn's disease	0.000134	0.00165	CcSEcCtD
Naratriptan—Fatigue—Prednisone—Crohn's disease	0.000129	0.00158	CcSEcCtD
Naratriptan—Constipation—Prednisone—Crohn's disease	0.000128	0.00157	CcSEcCtD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	0.000124	0.00756	CbGpPWpGaD
Naratriptan—Feeling abnormal—Prednisone—Crohn's disease	0.000123	0.00151	CcSEcCtD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	0.000121	0.0074	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—MLN—Crohn's disease	0.00012	0.00734	CbGpPWpGaD
Naratriptan—Urticaria—Prednisone—Crohn's disease	0.000119	0.00146	CcSEcCtD
Naratriptan—Body temperature increased—Prednisone—Crohn's disease	0.000118	0.00145	CcSEcCtD
Naratriptan—HTR1A—G alpha (i) signalling events—CCR9—Crohn's disease	0.000116	0.00709	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—ACKR2—Crohn's disease	0.000115	0.00703	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.000115	0.00703	CbGpPWpGaD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.000113	0.00689	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.000113	0.00688	CbGpPWpGaD
Naratriptan—Hypersensitivity—Prednisone—Crohn's disease	0.00011	0.00135	CcSEcCtD
Naratriptan—HTR1F—Signaling by GPCR—MLN—Crohn's disease	0.000109	0.00666	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—CCR9—Crohn's disease	0.000108	0.00658	CbGpPWpGaD
Naratriptan—Asthenia—Prednisone—Crohn's disease	0.000107	0.00132	CcSEcCtD
Naratriptan—HTR1A—GPCR ligand binding—ACKR2—Crohn's disease	0.000107	0.00653	CbGpPWpGaD
Naratriptan—Pruritus—Prednisone—Crohn's disease	0.000106	0.0013	CcSEcCtD
Naratriptan—HTR1D—G alpha (i) signalling events—CCR6—Crohn's disease	0.000103	0.0063	CbGpPWpGaD
Naratriptan—Diarrhoea—Prednisone—Crohn's disease	0.000102	0.00126	CcSEcCtD
Naratriptan—HTR1A—GPCR ligand binding—MLN—Crohn's disease	0.000101	0.00619	CbGpPWpGaD
Naratriptan—HTR1B—G alpha (i) signalling events—CCR6—Crohn's disease	0.000101	0.00616	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—GPR65—Crohn's disease	0.0001	0.00612	CbGpPWpGaD
Naratriptan—Dizziness—Prednisone—Crohn's disease	9.88e-05	0.00121	CcSEcCtD
Naratriptan—HTR1F—GPCR ligand binding—CCR6—Crohn's disease	9.75e-05	0.00596	CbGpPWpGaD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—CCR6—Crohn's disease	9.56e-05	0.00584	CbGpPWpGaD
Naratriptan—Vomiting—Prednisone—Crohn's disease	9.5e-05	0.00117	CcSEcCtD
Naratriptan—Rash—Prednisone—Crohn's disease	9.42e-05	0.00116	CcSEcCtD
Naratriptan—HTR1D—GPCR ligand binding—CCR9—Crohn's disease	9.42e-05	0.00575	CbGpPWpGaD
Naratriptan—Dermatitis—Prednisone—Crohn's disease	9.42e-05	0.00116	CcSEcCtD
Naratriptan—Headache—Prednisone—Crohn's disease	9.36e-05	0.00115	CcSEcCtD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—CCR6—Crohn's disease	9.36e-05	0.00572	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	9.22e-05	0.00564	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—CCR9—Crohn's disease	9.22e-05	0.00563	CbGpPWpGaD
Naratriptan—Nausea—Prednisone—Crohn's disease	8.88e-05	0.00109	CcSEcCtD
Naratriptan—HTR1D—GPCR ligand binding—GPR65—Crohn's disease	8.75e-05	0.00535	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—PTGER4—Crohn's disease	8.59e-05	0.00525	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	8.57e-05	0.00524	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—GPR65—Crohn's disease	8.57e-05	0.00524	CbGpPWpGaD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—PTGER4—Crohn's disease	8.42e-05	0.00514	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—CCR9—Crohn's disease	8.32e-05	0.00509	CbGpPWpGaD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—PTGER4—Crohn's disease	8.24e-05	0.00504	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	8.19e-05	0.00501	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	8.02e-05	0.0049	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—GPR65—Crohn's disease	7.74e-05	0.00473	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—CCR6—Crohn's disease	7.68e-05	0.0047	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—MLN—Crohn's disease	7.68e-05	0.00469	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—CCR9—Crohn's disease	7.56e-05	0.00462	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—MLN—Crohn's disease	7.52e-05	0.00459	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—IL10—Crohn's disease	7.39e-05	0.00452	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—ACKR2—Crohn's disease	7.35e-05	0.00449	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	7.21e-05	0.00441	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—ACKR2—Crohn's disease	7.2e-05	0.0044	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—CCR6—Crohn's disease	7.13e-05	0.00436	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	7.06e-05	0.00432	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—GPR65—Crohn's disease	7.03e-05	0.00429	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—CCR9—Crohn's disease	7.02e-05	0.00429	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—MLN—Crohn's disease	6.97e-05	0.00426	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—MLN—Crohn's disease	6.83e-05	0.00417	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—ACKR2—Crohn's disease	6.79e-05	0.00415	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—GPR65—Crohn's disease	6.53e-05	0.00399	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—MLN—Crohn's disease	6.44e-05	0.00394	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—IL10—Crohn's disease	6.29e-05	0.00384	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—PTGER4—Crohn's disease	6.28e-05	0.00384	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—CCR6—Crohn's disease	6.24e-05	0.00381	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	6.11e-05	0.00373	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—CCR6—Crohn's disease	6.11e-05	0.00373	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—TAGAP—Crohn's disease	5.89e-05	0.0036	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—MLN—Crohn's disease	5.73e-05	0.0035	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—CCR6—Crohn's disease	5.51e-05	0.00337	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—PTGER4—Crohn's disease	5.49e-05	0.00336	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—ACKR2—Crohn's disease	5.49e-05	0.00335	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	5.38e-05	0.00329	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—PTGER4—Crohn's disease	5.38e-05	0.00329	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—CCR9—Crohn's disease	5.32e-05	0.00325	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—CCR9—Crohn's disease	5.21e-05	0.00318	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—MLN—Crohn's disease	5.2e-05	0.00318	CbGpPWpGaD
Naratriptan—HTR1F—G alpha (i) signalling events—CXCL8—Crohn's disease	5.19e-05	0.00317	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—RSPO3—Crohn's disease	5.15e-05	0.00315	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—CCR6—Crohn's disease	5.01e-05	0.00306	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—GPR65—Crohn's disease	4.95e-05	0.00302	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—SEL1L—Crohn's disease	4.88e-05	0.00298	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—PTGER4—Crohn's disease	4.85e-05	0.00297	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—GPR65—Crohn's disease	4.84e-05	0.00296	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—CCR9—Crohn's disease	4.83e-05	0.00295	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—CCR9—Crohn's disease	4.73e-05	0.00289	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—CCR6—Crohn's disease	4.65e-05	0.00284	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—GPR65—Crohn's disease	4.49e-05	0.00275	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CCR9—Crohn's disease	4.46e-05	0.00273	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—PTGER4—Crohn's disease	4.41e-05	0.00269	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—GPR65—Crohn's disease	4.4e-05	0.00269	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—ACKR2—Crohn's disease	4.34e-05	0.00265	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—ACKR2—Crohn's disease	4.25e-05	0.0026	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—GPR65—Crohn's disease	4.15e-05	0.00254	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—IL3—Crohn's disease	4.13e-05	0.00253	CbGpPWpGaD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	4.13e-05	0.00252	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MLN—Crohn's disease	4.12e-05	0.00252	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—PTGER4—Crohn's disease	4.1e-05	0.0025	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—CXCL8—Crohn's disease	4.04e-05	0.00247	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MLN—Crohn's disease	4.03e-05	0.00246	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—RASGRP1—Crohn's disease	4e-05	0.00244	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—CCR9—Crohn's disease	3.97e-05	0.00243	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PLA2G4F—Crohn's disease	3.95e-05	0.00242	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—IL1B—Crohn's disease	3.88e-05	0.00237	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—TAGAP—Crohn's disease	3.77e-05	0.0023	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—IL3—Crohn's disease	3.75e-05	0.00229	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—GPR65—Crohn's disease	3.69e-05	0.00226	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—TAGAP—Crohn's disease	3.69e-05	0.00225	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—RASGRP1—Crohn's disease	3.63e-05	0.00222	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CCR9—Crohn's disease	3.6e-05	0.0022	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—CCR6—Crohn's disease	3.53e-05	0.00215	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—CCR6—Crohn's disease	3.45e-05	0.00211	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—CXCL8—Crohn's disease	3.44e-05	0.0021	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—MTMR3—Crohn's disease	3.36e-05	0.00205	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—GPR65—Crohn's disease	3.35e-05	0.00205	CbGpPWpGaD
Naratriptan—HTR1D—G alpha (i) signalling events—CXCL8—Crohn's disease	3.32e-05	0.00203	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—IL1B—Crohn's disease	3.3e-05	0.00201	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—RSPO3—Crohn's disease	3.29e-05	0.00201	CbGpPWpGaD
Naratriptan—HTR1B—G alpha (i) signalling events—CXCL8—Crohn's disease	3.25e-05	0.00199	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ACKR2—Crohn's disease	3.24e-05	0.00198	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—RSPO3—Crohn's disease	3.22e-05	0.00197	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—CCR6—Crohn's disease	3.2e-05	0.00196	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—CXCL8—Crohn's disease	3.14e-05	0.00192	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—CCR6—Crohn's disease	3.13e-05	0.00192	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—SEL1L—Crohn's disease	3.12e-05	0.00191	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—PTGER4—Crohn's disease	3.1e-05	0.0019	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MLN—Crohn's disease	3.07e-05	0.00188	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—SEL1L—Crohn's disease	3.06e-05	0.00187	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—PTGER4—Crohn's disease	3.04e-05	0.00186	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CCR6—Crohn's disease	2.96e-05	0.00181	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—IL2RA—Crohn's disease	2.9e-05	0.00177	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CCR9—Crohn's disease	2.85e-05	0.00174	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—PTGER4—Crohn's disease	2.82e-05	0.00172	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—TNF—Crohn's disease	2.81e-05	0.00172	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—TAGAP—Crohn's disease	2.81e-05	0.00172	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CCR9—Crohn's disease	2.8e-05	0.00171	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—PTGER4—Crohn's disease	2.76e-05	0.00169	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—RBX1—Crohn's disease	2.67e-05	0.00163	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—GPR65—Crohn's disease	2.65e-05	0.00162	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—IL3—Crohn's disease	2.64e-05	0.00162	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	2.64e-05	0.00161	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—IL2RA—Crohn's disease	2.63e-05	0.00161	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—CCR6—Crohn's disease	2.63e-05	0.00161	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—FADS1—Crohn's disease	2.62e-05	0.0016	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—PTGER4—Crohn's disease	2.6e-05	0.00159	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—GPR65—Crohn's disease	2.6e-05	0.00159	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—IL3—Crohn's disease	2.59e-05	0.00158	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	2.58e-05	0.00158	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—RASGRP1—Crohn's disease	2.56e-05	0.00156	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—RASGRP1—Crohn's disease	2.5e-05	0.00153	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—CXCL8—Crohn's disease	2.48e-05	0.00151	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—RSPO3—Crohn's disease	2.46e-05	0.0015	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—GPX4—Crohn's disease	2.45e-05	0.0015	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—IL3—Crohn's disease	2.4e-05	0.00147	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—TNF—Crohn's disease	2.39e-05	0.00146	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CCR6—Crohn's disease	2.39e-05	0.00146	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—GCKR—Crohn's disease	2.37e-05	0.00145	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—IL3—Crohn's disease	2.35e-05	0.00144	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—UBE2D1—Crohn's disease	2.34e-05	0.00143	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—SEL1L—Crohn's disease	2.33e-05	0.00142	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—RASGRP1—Crohn's disease	2.32e-05	0.00142	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—PTGER4—Crohn's disease	2.31e-05	0.00141	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—RIPK2—Crohn's disease	2.27e-05	0.00139	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—RASGRP1—Crohn's disease	2.27e-05	0.00139	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—IL6—Crohn's disease	2.27e-05	0.00139	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—IL3—Crohn's disease	2.22e-05	0.00136	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—RASGRP1—Crohn's disease	2.14e-05	0.00131	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CCR9—Crohn's disease	2.13e-05	0.0013	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—PTGER4—Crohn's disease	2.1e-05	0.00128	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—CXCL8—Crohn's disease	2.01e-05	0.00123	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—GPR65—Crohn's disease	1.98e-05	0.00121	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—IL3—Crohn's disease	1.97e-05	0.0012	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	1.97e-05	0.0012	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—CXCL8—Crohn's disease	1.97e-05	0.0012	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—JAK2—Crohn's disease	1.95e-05	0.00119	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—SOCS1—Crohn's disease	1.94e-05	0.00119	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—IL6—Crohn's disease	1.93e-05	0.00118	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—RASGRP1—Crohn's disease	1.91e-05	0.00117	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CCR6—Crohn's disease	1.89e-05	0.00116	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—TYK2—Crohn's disease	1.85e-05	0.00113	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—IL2RA—Crohn's disease	1.85e-05	0.00113	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CCR6—Crohn's disease	1.85e-05	0.00113	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—IL2RA—Crohn's disease	1.81e-05	0.00111	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—IL3—Crohn's disease	1.79e-05	0.00109	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—CXCL8—Crohn's disease	1.78e-05	0.00109	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—JAK2—Crohn's disease	1.77e-05	0.00108	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—RASGRP1—Crohn's disease	1.73e-05	0.00106	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—RBX1—Crohn's disease	1.71e-05	0.00105	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—IL2RA—Crohn's disease	1.68e-05	0.00103	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—SMAD3—Crohn's disease	1.68e-05	0.00103	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—RBX1—Crohn's disease	1.67e-05	0.00102	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PTGER4—Crohn's disease	1.66e-05	0.00102	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—IL2RA—Crohn's disease	1.65e-05	0.00101	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PTGER4—Crohn's disease	1.63e-05	0.000996	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—CXCL8—Crohn's disease	1.61e-05	0.000986	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—IL2RA—Crohn's disease	1.55e-05	0.000949	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—UBE2D1—Crohn's disease	1.5e-05	0.000916	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—CXCL8—Crohn's disease	1.5e-05	0.000916	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—UBE2D1—Crohn's disease	1.47e-05	0.000897	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—RIPK2—Crohn's disease	1.45e-05	0.000889	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—RIPK2—Crohn's disease	1.42e-05	0.00087	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IL3—Crohn's disease	1.42e-05	0.000867	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CCR6—Crohn's disease	1.41e-05	0.000862	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IL3—Crohn's disease	1.39e-05	0.000849	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—IL2RA—Crohn's disease	1.38e-05	0.000844	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—RASGRP1—Crohn's disease	1.37e-05	0.000838	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—RASGRP1—Crohn's disease	1.34e-05	0.000821	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—RBX1—Crohn's disease	1.28e-05	0.00078	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—IL2RA—Crohn's disease	1.25e-05	0.000767	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—JAK2—Crohn's disease	1.24e-05	0.000761	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—SOCS1—Crohn's disease	1.24e-05	0.000759	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PTGER4—Crohn's disease	1.24e-05	0.000759	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—JAK2—Crohn's disease	1.22e-05	0.000745	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—SOCS1—Crohn's disease	1.22e-05	0.000744	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—TYK2—Crohn's disease	1.18e-05	0.000724	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—TYK2—Crohn's disease	1.16e-05	0.000709	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—CXCL8—Crohn's disease	1.14e-05	0.000694	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—JAK2—Crohn's disease	1.13e-05	0.000691	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—UBE2D1—Crohn's disease	1.12e-05	0.000684	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—CXCL8—Crohn's disease	1.11e-05	0.00068	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—JAK2—Crohn's disease	1.11e-05	0.000676	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—TYK2—Crohn's disease	1.09e-05	0.000669	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—RIPK2—Crohn's disease	1.08e-05	0.000663	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—SMAD3—Crohn's disease	1.07e-05	0.000656	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IL3—Crohn's disease	1.06e-05	0.000646	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—SMAD3—Crohn's disease	1.05e-05	0.000642	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—JAK2—Crohn's disease	1.04e-05	0.000638	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—CXCL8—Crohn's disease	1.03e-05	0.00063	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—RASGRP1—Crohn's disease	1.02e-05	0.000625	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—CXCL8—Crohn's disease	1.01e-05	0.000617	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IL2RA—Crohn's disease	9.93e-06	0.000607	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IL2RA—Crohn's disease	9.73e-06	0.000594	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CXCL8—Crohn's disease	9.53e-06	0.000582	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—JAK2—Crohn's disease	9.28e-06	0.000567	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—SOCS1—Crohn's disease	9.27e-06	0.000566	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—IL6—Crohn's disease	9.06e-06	0.000554	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—TYK2—Crohn's disease	8.84e-06	0.00054	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—CXCL8—Crohn's disease	8.47e-06	0.000518	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—JAK2—Crohn's disease	8.43e-06	0.000515	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—SMAD3—Crohn's disease	8e-06	0.000489	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CXCL8—Crohn's disease	7.69e-06	0.00047	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—STAT3—Crohn's disease	7.66e-06	0.000468	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—ALB—Crohn's disease	7.54e-06	0.000461	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IL2RA—Crohn's disease	7.41e-06	0.000453	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—TYK2—Crohn's disease	7e-06	0.000428	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—TYK2—Crohn's disease	6.85e-06	0.000419	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—JAK2—Crohn's disease	6.68e-06	0.000408	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PTGS2—Crohn's disease	6.59e-06	0.000403	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—JAK2—Crohn's disease	6.54e-06	0.0004	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CXCL8—Crohn's disease	6.09e-06	0.000372	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CXCL8—Crohn's disease	5.97e-06	0.000365	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—IL6—Crohn's disease	5.79e-06	0.000354	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—IL6—Crohn's disease	5.67e-06	0.000347	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—IL6—Crohn's disease	5.35e-06	0.000327	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—TYK2—Crohn's disease	5.22e-06	0.000319	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—JAK2—Crohn's disease	4.98e-06	0.000304	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—STAT3—Crohn's disease	4.9e-06	0.000299	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—STAT3—Crohn's disease	4.8e-06	0.000293	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CXCL8—Crohn's disease	4.55e-06	0.000278	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—IL6—Crohn's disease	4.32e-06	0.000264	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—STAT3—Crohn's disease	3.66e-06	0.000223	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IL6—Crohn's disease	3.42e-06	0.000209	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IL6—Crohn's disease	3.35e-06	0.000205	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IL6—Crohn's disease	2.55e-06	0.000156	CbGpPWpGaD
